Savara appoints Braden Parker as chief commercial officer

Savara announced the appointment of Braden Parker as chief commercial officer, effective immediately. Parker is responsible for overseeing Savara’s global commercial strategy for molgramostim inhalation solution in autoimmune Pulmonary Alveolar Proteinosis, or aPAP. Parker joins Savara from Orchard Therapeutics, where he served as chief commercial officer.